Heron Therapeutics Inc (HRTX)
1.99
-0.06
(-2.93%)
USD |
NASDAQ |
Sep 27, 16:00
2.00
+0.01
(+0.50%)
After-Hours: 20:00
Heron Therapeutics SG&A Expense (TTM): 102.15M for June 30, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 102.15M |
March 31, 2024 | 115.43M |
December 31, 2023 | 126.00M |
September 30, 2023 | 129.08M |
June 30, 2023 | 132.66M |
March 31, 2023 | 123.98M |
December 31, 2022 | 119.95M |
September 30, 2022 | 127.62M |
June 30, 2022 | 134.44M |
March 31, 2022 | 135.48M |
December 31, 2021 | 127.33M |
September 30, 2021 | 121.01M |
June 30, 2021 | 108.02M |
March 31, 2021 | 100.27M |
December 31, 2020 | 106.08M |
September 30, 2020 | 108.32M |
June 30, 2020 | 111.89M |
March 31, 2020 | 119.91M |
December 31, 2019 | 127.66M |
September 30, 2019 | 126.06M |
June 30, 2019 | 124.06M |
March 31, 2019 | 111.37M |
December 31, 2018 | 93.87M |
September 30, 2018 | 88.02M |
June 30, 2018 | 84.44M |
Date | Value |
---|---|
March 31, 2018 | 84.66M |
December 31, 2017 | 82.16M |
September 30, 2017 | 77.85M |
June 30, 2017 | 75.35M |
March 31, 2017 | 70.18M |
December 31, 2016 | 69.03M |
September 30, 2016 | 65.29M |
June 30, 2016 | 56.05M |
March 31, 2016 | 47.11M |
December 31, 2015 | 35.74M |
September 30, 2015 | 26.24M |
June 30, 2015 | 22.22M |
March 31, 2015 | 19.89M |
December 31, 2014 | 19.73M |
September 30, 2014 | 19.90M |
June 30, 2014 | 22.13M |
March 31, 2014 | 22.02M |
December 31, 2013 | 21.94M |
September 30, 2013 | 19.94M |
June 30, 2013 | 15.92M |
March 31, 2013 | 12.83M |
December 31, 2012 | 8.657M |
September 30, 2012 | 6.444M |
June 30, 2012 | 5.176M |
March 31, 2012 | 4.372M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
100.27M
Minimum
Mar 2021
135.48M
Maximum
Mar 2022
120.17M
Average
122.50M
Median
SG&A Expense (TTM) Benchmarks
Arcutis Biotherapeutics Inc | 209.24M |
Bioventus Inc | 321.37M |
NovaBay Pharmaceuticals Inc | 11.53M |
Palatin Technologies Inc | 13.34M |
iBio Inc | 11.67M |